Search - tctmd.com

Displaying 341 - 360 of 413

Sort: Relevancy | Date

News Daily News

Paper Raises Doubts About Need for Further Testing After Resolved Chest Pain

L.A. McKeown

September 24, 2012

News Daily News

Model Suggests Renal Denervation Cost-effective for Resistant Hypertension

September 13, 2012

News Industry News

Health-Economic Analysis Suggests Medtronic Symplicity™ Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension

September 12, 2012

News Daily News

Dabigatran Usage up, Both for A-fib and Off-Label Indications

September 12, 2012

Presentation

Cost-effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension

Presenter: B.P. Geisler

September 12, 2012

News Conference News ESC 2012

Noninvasive CT Angiography Plus CT Perfusion Shows Power to Diagnose Ischemic Lesions

August 28, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

FDA Officials Claim No Delay in US Innovative Medical Devices Compared with Europe

August 09, 2012

News Daily News

CREST: Similar Cost Effectiveness for Carotid Stenting, Surgery

L.A. McKeown

July 25, 2012

Presentation

Costs and Cost-effectiveness of CAS vs. CEA for Patients at Standard Surgical Risk

Presenter: K.R. Vilain

July 24, 2012

News Daily News

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Jason Kahn

July 17, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

Halving DES Use in Low-Risk Patients Could Save $200 Million Annually

Yael L. Maxwell

July 11, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

News Daily News

Un Cribado del AAA es Bueno para los Hombres y un Nuevo Cribado podría ser incluso Mejor

L.A. McKeown

July 09, 2012

News Daily News

AAA Screening Good for Men but Rescreening May Be Even Better

L.A. McKeown

July 09, 2012

Presentation

Cost-effectiveness of AAA Screening and Rescreening in Men

Presenter: Rikke S?gaard

July 06, 2012

News Industry News

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

June 26, 2012

News Daily News

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

June 26, 2012

Presentation

Cost-Effectiveness of Treating ACS Patients with Ticagrelor for 12 Months

Presenter: Elisabet Nikolic

June 25, 2012

Advertisement

Paper Raises Doubts About Need for Further Testing After Resolved Chest Pain

Model Suggests Renal Denervation Cost-effective for Resistant Hypertension

Health-Economic Analysis Suggests Medtronic Symplicity™ Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension

Dabigatran Usage up, Both for A-fib and Off-Label Indications

Cost-effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension

Noninvasive CT Angiography Plus CT Perfusion Shows Power to Diagnose Ischemic Lesions

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

FDA Officials Claim No Delay in US Innovative Medical Devices Compared with Europe

CREST: Similar Cost Effectiveness for Carotid Stenting, Surgery

Costs and Cost-effectiveness of CAS vs. CEA for Patients at Standard Surgical Risk

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Halving DES Use in Low-Risk Patients Could Save $200 Million Annually

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Un Cribado del AAA es Bueno para los Hombres y un Nuevo Cribado podría ser incluso Mejor

AAA Screening Good for Men but Rescreening May Be Even Better

Cost-effectiveness of AAA Screening and Rescreening in Men

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

Cost-Effectiveness of Treating ACS Patients with Ticagrelor for 12 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content